シェーグレン症候群・SLE・間質性肺疾患の合併例における分子状水素の免疫調節および疲労軽減効果：症例報告
A 69-year-old woman with concurrent Sjögren's syndrome, systemic lupus erythematosus (SLE), and interstitial lung disease (ILD) who had been receiving corticosteroids and immunomodulatory agents was given molecular hydrogen as an adjunct over several months. Clinical outcomes included resolution of xerostomia, insomnia, dyspnea, chest pain, and dizziness. Immunological assessments revealed favorable shifts in T and B lymphocyte subsets alongside reductions in inflammatory markers and improved pulmonary imaging. Fatigue decreased substantially, enabling corticosteroid tapering and reduced dependence on nocturnal oxygen supplementation. Continued hydrogen administration combined with high-dose vitamin C maintained disease stability and enhanced quality of life. The findings suggest that molecular hydrogen may offer immunomodulatory and antioxidant benefits as an adjunct in patients with overlapping autoimmune and pulmonary conditions who show inadequate responses to standard regimens.
Molecular hydrogen is proposed to exert anti-inflammatory, antioxidant, and immunomodulatory effects, leading to favorable shifts in T and B lymphocyte subsets and reductions in circulating inflammatory markers, thereby contributing to symptomatic stabilization.
This study combines multiple delivery routes. As a general principle, the most efficient route for routine hydrogen intake is inhalation. Inhalation carries explosion risk (empirical LFL of 10%; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/40579023